Tirzepatide for MASH: What the SYNERGY-NASH Phase 2 Trial Actually Showed

Tirzepatide is best known as the dual GIP/GLP-1 receptor agonist marketed for type 2 diabetes and for chronic weight management. But one of the most-discussed datasets around the molecule concerns a different organ entirely: the liver. In 2024, the New England Journal of Medicine published results from SYNERGY-NASH, a Phase 2 trial testing tirzepatide in people with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH, the condition formerly called NASH). This is a research log, so let's separate what the trial measured from what it does not yet establish.

What SYNERGY-NASH was

SYNERGY-NASH was a multicenter, double-blind, randomized, placebo-controlled Phase 2 study. It enrolled 190 adults with biopsy-proven MASH and stage 2 or 3 liver fibrosis (moderate to advanced scarring, but not cirrhosis), with or without type 2 diabetes. Participants were randomized to weekly subcutaneous tirzepatide at 5 mg, 10 mg, or 15 mg, or to placebo, for 52 weeks, after which liver histology was reassessed by biopsy.

The key detail for interpreting any liver-disease trial is the endpoint. "Feeling better" or lower blood tests are not the bar; the field requires paired liver biopsies read by pathologists blinded to treatment.

The headline results, by dose

The primary endpoint was resolution of MASH (steatohepatitis) with no worsening of fibrosis at 52 weeks. The proportions who reached it climbed with dose:

Every tirzepatide dose was superior to placebo for this outcome. That is a large separation for a MASH trial, where placebo responses are often meaningful because lifestyle change and regression to the mean both push in the same direction.

A secondary endpoint looked at the harder-to-move target: improvement of at least one fibrosis stage without worsening of MASH. Here the reported figures were roughly 59% (5 mg), 53% (10 mg), and 54% (15 mg) versus about 33% on placebo. The signal is encouraging, but two caveats matter. First, the fibrosis endpoint was secondary and not adjusted for multiple comparisons, so it is best read as hypothesis-generating rather than confirmatory. Second, unlike the primary endpoint, the fibrosis benefit did not show a clean dose-response — the lowest dose numerically led. Tirzepatide also improved body weight, liver enzymes, and non-invasive markers of liver fat and inflammation. Side effects were predominantly gastrointestinal (nausea, diarrhea, decreased appetite, constipation) and mostly mild to moderate — consistent with the drug's known profile.

Why a GIP/GLP-1 drug would touch the liver at all

Tirzepatide is a single peptide that activates two incretin receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Neither receptor is the direct driver of liver scarring, which is part of why the mechanism in MASH is thought to be largely indirect. MASH sits downstream of insulin resistance, excess visceral and hepatic fat, and lipotoxic inflammation. By producing substantial weight loss, improving insulin sensitivity, and reducing the flux of fat and glucose that the liver has to process, incretin agonism can lower hepatic fat and the inflammatory pressure that fuels steatohepatitis. Whether GIP receptor activity adds a liver-specific benefit beyond GLP-1 alone — versus simply delivering more weight loss — is an open scientific question the Phase 2 data cannot resolve. You can read more about the molecule itself on our tirzepatide reference page.

This is not the same as its approved uses

This is the point most worth underlining. Tirzepatide's regulatory approvals are for type 2 diabetes and for chronic weight management — not for MASH. SYNERGY-NASH is a Phase 2 study: it is designed to test a hypothesis and size a larger program, not to serve as the pivotal evidence a regulator uses to approve a new indication. Phase 2 histology results, however striking, still have to be confirmed in larger and longer Phase 3 trials with clinical outcomes (progression to cirrhosis, liver-related events) before MASH becomes an established, approved use.

So the accurate framing today is: tirzepatide is investigational for MASH, with promising Phase 2 biopsy data and an ongoing development program, while its on-label uses remain metabolic. Regulatory status in this area is moving quickly and varies by country and by molecule, so treat any "approved for fatty liver" claim skeptically and check it against primary regulatory sources. For how PepStash frames approval status generally, see our FDA status reference.

The research-log takeaway

SYNERGY-NASH is one of the stronger incretin datasets in liver disease: a well-controlled Phase 2 with biopsy endpoints, a clear dose-dependent MASH-resolution signal, and a fibrosis signal worth confirming. It is also, by design, preliminary. Log it as promising Phase 2 evidence for an investigational indication — not as a settled treatment.

PepStash is a research log and reference tool. This article is educational and is not medical advice — it does not diagnose, treat, or recommend any protocol. Regulatory status and trial data change; always verify against primary sources and consult a licensed physician before making any decisions about your health.